Sarepta gets territorial rights to Summit's utrophin modulators

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) granted Sarepta Therapeutics Inc. (NASDAQ:SRPT) exclusive rights in Europe, Turkey and the Commonwealth of Independent States to Summit's utrophin ( UTRN) modulator pipeline to treat Duchenne muscular dystrophy (DMD). Summit jumped 122p (93%) to 252.50p in London on Tuesday, and gained $5.70 (66%) to $14.35 on NASDAQ.

The deal includes Summit's lead clinical candidate, ezutromid ( SMT C1100). The open-label Phase II PhaseOut DMD study of that compound began enrolling patients in June. ...